1. Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study
- Author
-
Valéria Valim, Ketty Lysie Libardi Lira Machado, Samira Tatiyama Miyamoto, Arthur Dalmaso Pinto, Priscila Costa Martins Rocha, Erica Vieira Serrano, Valquiria Garcia Dinis, Sônia Alves Gouvêa, João Gabriel Fragoso Dias, Ana Carolina Campi-Azevedo, Andréa Teixeira-Carvalho, Vanessa Peruhype-Magalhães, Ismael Artur da Costa-Rocha, Sheila Maria Barbosa de Lima, Emily Hime Miranda, Gisela Freitas Trindade, Maria de Lourdes de Sousa Maia, Maria Bernadete Renoldi de Oliveira Gavi, Lidia Balarini da Silva, Ruben Horst Duque, Ana Paula Espíndula Gianordoli, Thays Zanon Casagrande, Karine Gadioli Oliveira, Bruna Costa da Mata Moura, Fernanda Nicole-Batista, Luiza Correa Rodrigues, Thalles Brandão Clemente, Enan Sales Magalhães, Maria de Fatima Bissoli, Maria da Penha Gomes Gouvea, Lauro Ferreira da Silva Pinto-Neto, Carolina Zorzanelli Costa, Raquel Altoé Giovelli, Leticia Resende Brandão, Elizandra Tomazela Laurenti Polito, Ingrid de Oliveira Koehlert, Brunela Passos Borjaille, Daniela Bergamim Pereira, Laiza Hombre Dias, Daniela Linhares Merlo, Luiz Fellipe Favoreto Genelhu, Flavia Zon Pretti, Maryella dos Santos Giacomin, Ana Paula Neves Burian, Francieli Fontana Sutile Tardetti Fantinato, Gecilmara Salviato Pileggi, Lícia Maria Henrique da Mota, and Olindo Assis Martins-Filho
- Subjects
yellow fever vaccine ,autoimmune diseases ,viremia ,seroconversion ,pharmacokinetics ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Yellow Fever (YF) vaccination is suggested to induce a large number of adverse events (AE) and suboptimal responses in patients with autoimmune diseases (AID); however, there have been no studies on 17DD-YF primary vaccination performance in patients with AID. This prospective non-interventional study conducted between March and July, 2017 assessed the safety and immunogenicity of planned 17DD-YF primary vaccination in patients with AID. Adult patients with AID (both sexes) were enrolled, along with healthy controls, at a single hospital (Vitória, Brazil). Included patients were referred for planned vaccination by a rheumatologist; in remission, or with low disease activity; and had low level immunosuppression or the attending physician advised interruption of immunosuppression for safety reasons. The occurrence of AE, neutralizing antibody kinetics, seropositivity rates, and 17DD-YF viremia were evaluated at various time points (day 0 (D0), D3, D4, D5, D6, D14, and D28). Individuals evaluated (n = 278), including patients with rheumatoid arthritis (RA; 79), spondyloarthritis (SpA; 59), systemic sclerosis (8), systemic lupus erythematosus (SLE; 27), primary Sjögren's syndrome (SS; 54), and healthy controls (HC; 51). Only mild AE were reported. The frequency of local and systemic AE in patients with AID and HC did not differ significantly (8 vs. 10% and 21 vs. 32%; p = 1.00 and 0.18, respectively). Patients with AID presented late seroconversion profiles according to kinetic timelines of the plaque reduction neutralization test (PRNT). PRNT-determined virus titers (copies/mL) [181 (95% confidence interval (CI), 144–228) vs. 440 (95% CI, 291–665), p = 0.004] and seropositivity rate (78 vs. 96%, p = 0.01) were lower in patients with AID after 28 days, particularly those with SpA (73%) and SLE (73%), relative to HC. The YF viremia peak (RNAnemia) was 5–6 days after vaccination in all groups. In conclusion, consistent seroconversion rates were observed in patients with AID and our findings support that planned 17DD-YF primary vaccination is safe and immunogenic in patients with AID.
- Published
- 2020
- Full Text
- View/download PDF